Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) announced the successful completion of a pilot project with Kuano Ltd. that supports the advancement of the company’s PNKP Inhibitor Technology (ONC010). The collaboration utilized AI-enabled and quantum-based computational analysis to enhance understanding of how the PNKP inhibitor and related analogs interact with their target.
Kuano delivered molecular modeling and computational findings that strengthened Onco’s understanding of its PNKP inhibitor, producing a refined structural hypothesis for PNKP inhibition. The project also applied quantum-based computational methods to assess PNKP structural behavior and develop human PNKP structural models for follow-on analysis. According to the company, the results are expected to support future initiatives including quantum-based QSAR modeling, toxicity mapping and AI-assisted generative compound design, with the goal of improving compound prioritization and accelerating progress toward preclinical development.
This development is significant for Onco-Innovations as it moves its oncology pipeline forward. The company is dedicated to cancer research and treatment, specializing in oncology, and has secured an exclusive worldwide license to patented technology that targets solid tumours. The successful pilot marks a key step in refining its drug discovery process, potentially leading to more effective cancer therapies.
For more details, the full press release is available at https://ibn.fm/SdQqD. The latest news and updates relating to ONNVF are available in the company’s newsroom at https://ibn.fm/ONNVF.
